Chemical and Pharmaceutical Bulletin
Online ISSN : 1347-5223
Print ISSN : 0009-2363
ISSN-L : 0009-2363
Communication to the Editor
Enzymatic Stability of Myostatin Inhibitory 16-mer Peptides
Kentaro TakayamaMiki OdagiriAkihiro TaguchiAtsuhiko TaniguchiYoshio Hayashi
Author information
Supplementary material

2020 Volume 68 Issue 6 Pages 512-515


Inhibition of myostatin is a promising strategy for treatment of muscle atrophic disorders. A 16-mer myostatin inhibitory linear peptide, MIPE-1686, administered intramuscularly, significantly increases muscle mass and hindlimb grip strength in Duchenne muscular dystrophic model mice. In this paper, we describe our examination of the enzymatic stabilities of this peptide with recombinant human proteases, aminopeptidase N, chymotrypsin C, and trypsin 3. MIPE-1686 was found to be stable in the presence of these enzymes, in contrast to a peptide (1), from which MIPE-1686 was developed. Modification of the peptides at a position distant from the protease cleavage site altered their enzymatic stability. These results suggest the possibility that the stability to proteases of 16-mer myostatin inhibitory peptides is associated with an increase in their known β-sheet formation properties. This study suggests that MIPE-1686 has a potential to serve as a long-lasting agent in vivo.

Graphical Abstract Fullsize Image
Content from these authors
© 2020 The Pharmaceutical Society of Japan
Previous article Next article